Novacyt (NVYTF)
OTHER OTC:NVYTF
Want to see NVYTF full AI Analyst Report?
NVYTF Stock Chart & Stats
$0.52
$0.02(2.62%)
At close: 4:00 PM EST
$0.52
$0.02(2.62%)
Day’s Range― - ―
52-Week Range$0.48 - $0.61
Previous CloseN/A
Volume300.00
Average Volume (3M)0.00
Market Cap
$53.09M
Enterprise Value$30.74M
Total Cash (Recent Filing)$19.14M
Total Debt (Recent Filing)$10.44M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding72,588,090
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.03
Price to Sales (P/S)1.18
P/FCF Ratio-2.67
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue1.53
Enterprise Value/Gross Profit3.06
Enterprise Value/Ebitda-3.42
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$35.61M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained high blended gross margins (63%) driven by PCR/RUO kits and Primerdesign (>80%) create durable product-level profitability. This margin profile supports operating leverage as volumes scale, makes the business less sensitive to input-cost swings, and underpins a realistic path to EBITDA breakeven if revenue growth continues.
Instrument And Product MomentumGrowing instrument sales (LightBench) plus new assay launches create a recurring consumables attach model: instruments drive long-term reagent pull-through, higher customer stickiness and cross-sell. Durable product momentum diversifies revenue beyond single-test cycles and supports sustainable top-line expansion if adoption persists.
IVDR Regulatory PositioningIVDR accreditation raises regulatory barriers to entry, reducing competitor re-entry risk and supporting market access in regulated markets. Durable regulatory certification can protect pricing and adoption for core assays, making revenue streams more predictable and improving long-term commercial defensibility.
Bears Say
Low Cash And Ongoing BurnMaterial cash depletion and ~£825k monthly burn create financing risk absent sustained operational improvement. Limited runway increases probability of dilutive funding, covenant pressure, or constrained investment in sales/R&D, making execution on revenue and integration targets contingent and raising medium-term survival risk.
Structural UnprofitabilityMulti-year operating losses and negative free cash flow (2022–2025) indicate the current revenue base does not cover the cost structure. Until revenue scales materially or cost base contracts sustainably, profitability targets remain speculative, limiting internal cash generation and increasing reliance on external financing.
Large Impairments And Exceptional ChargesSignificant non-cash impairments signal prior overpayment or underperformance of acquisitions and erode equity cushions. Repeated large write-downs reduce flexibility for M&A, raise governance questions on capital allocation, and increase the likelihood of future impairments if growth or margin improvements falter.
Novacyt News
NVYTF FAQ
What was Novacyt’s price range in the past 12 months?
Novacyt lowest stock price was $0.48 and its highest was $0.61 in the past 12 months.
What is Novacyt’s market cap?
Novacyt’s market cap is $53.09M.
When is Novacyt’s upcoming earnings report date?
Novacyt’s upcoming earnings report date is Sep 24, 2026 which is in 126 days.
How were Novacyt’s earnings last quarter?
Novacyt released its earnings results on Apr 30, 2026. The company reported -$0.317 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.317.
Is Novacyt overvalued?
According to Wall Street analysts Novacyt’s price is currently Overvalued.
Does Novacyt pay dividends?
Novacyt does not currently pay dividends.
What is Novacyt’s EPS estimate?
Novacyt’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novacyt have?
Novacyt has 72,588,090 shares outstanding.
What happened to Novacyt’s price movement after its last earnings report?
Novacyt reported an EPS of -$0.317 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Novacyt?
Currently, no hedge funds are holding shares in NVYTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novacyt
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
NVYTF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented clear operational and strategic progress: revenue growth, product launches (LightBench Discover, DPYD), strong gross margin (63%), reduced OpEx and a narrowing of reported losses. Management completed an earnings-accretive acquisition (Southern Cross) and emphasized regulatory strength via IVDR approvals. Material headwinds remain — notably a large non-cash impairment (~GBP 14.4m), exceptional charges (~GBP 16m), reduced cash to GBP 11m at end-March 2026 and ongoing operating losses — but management articulated a clear plan to accelerate top-line growth and reduce cash burn. Highlights and lowlights are balanced: tangible improvements and growth catalysts exist, yet meaningful financial and execution risks persist in the near term.View all NVYTF earnings summariesTechnical Analysis
MAUNA KEA TECHNOLOGIES
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―
Ownership Overview
Options Prices
Currently, No data available
---